Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 24,900 shares, an increase of 6.4% from the February 13th total of 23,400 shares. Based on an average daily trading volume, of 5,800 shares, the short-interest ratio is currently 4.3 days. Currently, 0.5% of the company’s stock are sold short.
Anebulo Pharmaceuticals Stock Down 6.0 %
Shares of ANEB stock opened at $2.51 on Thursday. The company has a 50 day moving average of $2.89 and a 200-day moving average of $2.83. Anebulo Pharmaceuticals has a 12-month low of $1.77 and a 12-month high of $7.73. The firm has a market cap of $64.34 million, a P/E ratio of -5.70 and a beta of -1.43.
Analysts Set New Price Targets
Separately, Benchmark decreased their price objective on shares of Anebulo Pharmaceuticals from $10.00 to $8.00 and set a “speculative buy” rating for the company in a research note on Tuesday, February 14th.
Institutional Investors Weigh In On Anebulo Pharmaceuticals
Anebulo Pharmaceuticals Company Profile
Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.
- Get a free copy of the StockNews.com research report on Anebulo Pharmaceuticals (ANEB)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.